Chronic superficial gastritis is “widespread”: Chronic superficial gastritis is the most common type of chronic gastritis, with a clinical detection rate of 80-90%. In some hospitals, if you undergo a gastroscopy, you will almost invariably receive a diagnosis of chronic superficial gastritis at the mildest level. Clinicians rarely see a normal gastroscopy report with “no abnormalities in the stomach or duodenum”. In fact, many gastroscopy reports of chronic superficial gastritis are simply functional dyspepsia or non-ulcer dyspepsia, not true chronic inflammation of the gastric mucosa. Asymptomatic without treatment: Should chronic superficial gastritis be treated? This should be determined by the presence or absence of symptoms. For people who have chronic superficial gastritis as reported by gastroscopy without any symptoms, no treatment is needed. If there are symptoms such as loss of appetite, upper abdominal discomfort, vague pain, belching, acid reflux or nausea and vomiting, then symptomatic treatment is needed. For example, for people with fullness, nausea and vomiting, multi-enzyme tablets and various probiotics can be taken; for people with bile reflux, in addition to gastric motility drugs (such as morpholine) to prevent bile reflux, some bile-neutralizing drugs, such as chewable magnesium aluminum carbonate, should be used; for people with stomach cramps, belladonna tablets and 654-2 can be used to relieve spasm and pain; and for people with acid reflux and abdominal pain, PPI preparations (such as omeprazole), etc. to treat. Some patients with chronic superficial gastritis also have H. pylori (Hp) infection, should they be treated with H. pylori eradication therapy? The principle also depends on the symptoms: asymptomatic patients do not need treatment, while symptomatic patients need Hp eradication therapy, which can improve dyspeptic symptoms. In addition, H. pylori eradication can also reduce chronic inflammation of the gastric mucosa, thus preventing the occurrence of peptic ulcers; this can also largely prevent gastric mucosal atrophy, which may reduce the incidence of gastric cancer. Hearing about the relationship between H. pylori and gastric cancer may create fear in patients infected with H. pylori; some people strongly request Hp eradication treatment even if they have no gastrointestinal symptoms. For such patients, Hp eradication treatment can also be performed to eliminate the psychogenic disease, and the patient will be comfortable.